Vincristine News and Research

RSS
Vincristine is the active ingredient in a drug used to treat acute leukemia. It is used in combination with other drugs to treat Hodgkin disease, non-Hodgkin lymphoma, rhabdomyosarcoma, neuroblastoma, and Wilms tumor. Vincristine is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division. It is a type of vinca alkaloid and a type of antimitotic agent.
Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Best available chemotherapy for HIV-related Kaposi sarcoma would save lives and be cost-effective in Africa

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Ibrutinib plus standard chemotherapy effective in younger patients with diffuse large B-cell lymphoma

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

Sunitinib extends progression-free survival in patients with rare neuroendocrine tumor, study shows

Younger children more vulnerable to chemotherapy-related hearing loss, study finds

Younger children more vulnerable to chemotherapy-related hearing loss, study finds

Chemotherapy drug can cause permanent hearing loss in young children with cancer

Chemotherapy drug can cause permanent hearing loss in young children with cancer

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

International collaboration aims to develop better therapy for childhood acute lymphoblastic leukemia

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Chemotherapy drugs can induce mutations that lead to relapse in pediatric ALL patients

Research shines new light on deadly medulloblastoma metastases

Research shines new light on deadly medulloblastoma metastases

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Kinase inhibitors could provide an effective way to treat high-risk leukaemia

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Targeted therapy achieves excellent outcomes, reduces side effects in high-risk Hodgkin lymphoma

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Review helps understand the mechanisms of R-CHOP resistance in diffuse large B-cell lymphoma

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Study characterizes cisplatin-induced hearing loss in pediatric cancer patients

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Chemotherapy combined with blinatumomab increases survival for patients with Ph-negative B-ALL

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Adjuvant chemotherapy can improve overall survival in patients with high-risk, low-grade glioma

Adjuvant chemotherapy can improve overall survival in patients with high-risk, low-grade glioma

Scientists develop new method for targeted drug delivery to cancer cells

Scientists develop new method for targeted drug delivery to cancer cells

Scientists develop a method of targeted drug delivery to cancer cells

Scientists develop a method of targeted drug delivery to cancer cells

Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

Study shows both IDH-mutant WHO-defined molecular subgroups could benefit from PCV chemoradiotherapy

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma

First biosimilar approved by FDA for treatment of adult patients with non-Hodgkin’s lymphoma